415 related articles for article (PubMed ID: 28709995)
1. The contribution of biophysical and structural studies of protein self-assembly to the design of therapeutic strategies for amyloid diseases.
Cremades N; Dobson CM
Neurobiol Dis; 2018 Jan; 109(Pt B):178-190. PubMed ID: 28709995
[TBL] [Abstract][Full Text] [Related]
2. Structure and intermolecular dynamics of aggregates populated during amyloid fibril formation studied by hydrogen/deuterium exchange.
Carulla N; Zhou M; Giralt E; Robinson CV; Dobson CM
Acc Chem Res; 2010 Aug; 43(8):1072-9. PubMed ID: 20557067
[TBL] [Abstract][Full Text] [Related]
3. Phthalocyanines as Molecular Scaffolds to Block Disease-Associated Protein Aggregation.
Valiente-Gabioud AA; Miotto MC; Chesta ME; Lombardo V; Binolfi A; Fernández CO
Acc Chem Res; 2016 May; 49(5):801-8. PubMed ID: 27136297
[TBL] [Abstract][Full Text] [Related]
4. Structural studies on the mechanism of protein aggregation in age related neurodegenerative diseases.
Eftekharzadeh B; Hyman BT; Wegmann S
Mech Ageing Dev; 2016 Jun; 156():1-13. PubMed ID: 27005270
[TBL] [Abstract][Full Text] [Related]
5. Structural remodeling during amyloidogenesis of physiological Nα-acetylated α-synuclein.
Gallea JI; Sarroukh R; Yunes-Quartino P; Ruysschaert JM; Raussens V; Celej MS
Biochim Biophys Acta; 2016 May; 1864(5):501-10. PubMed ID: 26845568
[TBL] [Abstract][Full Text] [Related]
6. Protein aggregation and ER stress.
Ogen-Shtern N; Ben David T; Lederkremer GZ
Brain Res; 2016 Oct; 1648(Pt B):658-666. PubMed ID: 27037184
[TBL] [Abstract][Full Text] [Related]
7. AFM-Based Single Molecule Techniques: Unraveling the Amyloid Pathogenic Species.
Ruggeri FS; Habchi J; Cerreta A; Dietler G
Curr Pharm Des; 2016; 22(26):3950-70. PubMed ID: 27189600
[TBL] [Abstract][Full Text] [Related]
8. Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.
Meredith SC
Ann N Y Acad Sci; 2005 Dec; 1066():181-221. PubMed ID: 16533927
[TBL] [Abstract][Full Text] [Related]
9. Pathways of amyloid fibril formation and protein aggregation.
Tavili E; Aziziyan F; Dabirmanesh B
Prog Mol Biol Transl Sci; 2024; 206():11-54. PubMed ID: 38811078
[TBL] [Abstract][Full Text] [Related]
10. Combining molecular dynamics simulations and experimental analyses in protein misfolding.
Wille H; Dorosh L; Amidian S; Schmitt-Ulms G; Stepanova M
Adv Protein Chem Struct Biol; 2019; 118():33-110. PubMed ID: 31928730
[TBL] [Abstract][Full Text] [Related]
11. Protein misfolding, aggregation and mechanism of amyloid cytotoxicity: An overview and therapeutic strategies to inhibit aggregation.
Zaman M; Khan AN; Wahiduzzaman ; Zakariya SM; Khan RH
Int J Biol Macromol; 2019 Aug; 134():1022-1037. PubMed ID: 31128177
[TBL] [Abstract][Full Text] [Related]
12. Structural, morphological, and functional diversity of amyloid oligomers.
Breydo L; Uversky VN
FEBS Lett; 2015 Sep; 589(19 Pt A):2640-8. PubMed ID: 26188543
[TBL] [Abstract][Full Text] [Related]
13. Recent structural and computational insights into conformational diseases.
Fernàndez-Busquets X; de Groot NS; Fernandez D; Ventura S
Curr Med Chem; 2008; 15(13):1336-49. PubMed ID: 18537613
[TBL] [Abstract][Full Text] [Related]
14. Hemin as a generic and potent protein misfolding inhibitor.
Liu Y; Carver JA; Ho LH; Elias AK; Musgrave IF; Pukala TL
Biochem Biophys Res Commun; 2014 Nov; 454(2):295-300. PubMed ID: 25450392
[TBL] [Abstract][Full Text] [Related]
15. Liquid-liquid phase transitions and amyloid aggregation in proteins related to cancer and neurodegenerative diseases.
de Oliveira GAP; Cordeiro Y; Silva JL; Vieira TCRG
Adv Protein Chem Struct Biol; 2019; 118():289-331. PubMed ID: 31928729
[TBL] [Abstract][Full Text] [Related]
16. Propagation of Protein Aggregation in Neurodegenerative Diseases.
Vaquer-Alicea J; Diamond MI
Annu Rev Biochem; 2019 Jun; 88():785-810. PubMed ID: 30917002
[TBL] [Abstract][Full Text] [Related]
17. The Diagnostic Potential of Amyloidogenic Proteins.
Jin Y; Vadukul DM; Gialama D; Ge Y; Thrush R; White JT; Aprile FA
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923609
[TBL] [Abstract][Full Text] [Related]
18. Biophysical Aspects of Alzheimer's Disease: Implications for Pharmaceutical Sciences : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla.
Arosio P
Pharm Res; 2017 Dec; 34(12):2628-2636. PubMed ID: 28963701
[TBL] [Abstract][Full Text] [Related]
19. Protein misfolding in neurodegenerative diseases.
Agorogiannis EI; Agorogiannis GI; Papadimitriou A; Hadjigeorgiou GM
Neuropathol Appl Neurobiol; 2004 Jun; 30(3):215-24. PubMed ID: 15175075
[TBL] [Abstract][Full Text] [Related]
20. [Can prion-like propagation occur in neurodegenerative diseases?: in view of transmissible systemic amyloidosis].
Yoshida K; Higuchi K; Ikeda S
Brain Nerve; 2012 Jun; 64(6):665-74. PubMed ID: 22647474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
